arGentis Pharmaceuticals, LLC Receives Orphan Drug Designation for European Union

Published: Feb 17, 2009

MEMPHIS, Tenn.--(BUSINESS WIRE)--arGentis Pharmaceuticals, LLC announced today that the European Medicines Agency (EMEA) accepted the company’s product candidate ARG201 (native type 1 bovine collagen) for the treatment of diffuse systemic sclerosis, also known as systemic scleroderma (SSc) for designation as an orphan medicinal product in the European Union.

Back to news